Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.lupin.com | |
Market Cap | 33,760.86 Cr. | |
Enterprise Value(EV) | 36,904.38 Cr. | 2022-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 1.50 | Trailing Twelve Months Ending 2022-09 |
Price-Earning Ratio (PE) | 495.63 | Trailing Twelve Months Ending 2022-09 |
Industry PE | 32.90 | Trailing Twelve Months Ending 2022-09 |
Book Value / Share | 260.82 | Trailing Twelve Months Ending 2022-09 |
Price to Book Value | 2.85 | Calculated using Price: 743.00 |
Dividend Yield | 0.54 | Period Ending 2022-03 |
No. of Shares Subscribed | 45.49 Cr. | 454,875,499 Shares |
FaceValue | 2 | |
Company Profile | ||
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. Lupin is recognised as one of the world's largest manufacturers of Tuberculosis drugs. The company have significant market share across multiple therapy areas such as Cardiovascular (prils and statins), Diabetology, Asthma, Paediatric, Central Nervous System (CNS), Gastro Intestinal (GI), Anti-Infective (AI) and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). To add to this, the company has proud to maintain over the years its global leadership positions in other therapy areas such as Anti-TB and Cephalosporin. |
1 Day |
|
-0.44% |
1 Week |
|
-1.38% |
1 Month |
|
+0.16% |
3 Month |
|
+5.68% |
6 Month |
|
+16.05% |
1 Year |
|
-16.34% |
2 Year |
|
-30.84% |
5 Year |
|
-21.83% |
10 Year |
|
+23.94% |
9 years | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
Return on Equity (%) | 30.89 | 31.09 | 22.80 | 20.98 | 1.91 | 4.55 | -2.12 | 9.46 | -11.79 | |
Return on Capital Employed (%) | 40.97 | 40.30 | 24.38 | 18.53 | 3.54 | 8.45 | 6.02 | 9.70 | -7.11 | |
Return on Assets (%) | 19.70 | 21.08 | 12.82 | 10.57 | 0.99 | 2.32 | -1.05 | 5.09 | -6.70 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09* Rs. Cr. |
Shh. Funds | 6,932 | 8,874 | 11,163 | 13,498 | 13,577 | 13,742 | 12,537 | 13,803 | 12,153 | 11,864 | |
Non Curr. Liab. | 507 | 426 | 6,032 | 6,447 | 6,876 | 7,296 | 3,003 | 1,136 | 1,153 | 1,103 | |
Curr. Liab. | 2,630 | 3,729 | 5,061 | 6,121 | 5,096 | 6,130 | 9,225 | 8,436 | 8,276 | 8,488 | |
Minority Int. | 67 | 24 | 32 | 35 | 40 | 47 | 44 | 55 | 69 | 60 | |
Equity & Liab. | 10,135 | 13,054 | 22,289 | 26,100 | 25,589 | 27,215 | 24,810 | 23,430 | 21,651 | 21,515 | |
Non Curr. Assets | 4,035 | 5,221 | 12,402 | 14,147 | 13,379 | 13,362 | 9,396 | 9,444 | 9,194 | 9,668 | |
Curr. Assets | 6,100 | 7,832 | 9,887 | 11,953 | 12,210 | 13,854 | 15,413 | 13,986 | 12,458 | 11,847 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 10,135 | 13,054 | 22,289 | 26,100 | 25,589 | 27,215 | 24,810 | 23,430 | 21,651 | 21,515 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09 Rs. Cr. TTM |
Net Sales | 11,287 | 12,770 | 14,139 | 17,494 | 15,804 | 16,751 | 16,837 | 15,163 | 16,405 | 15,933 | |
Other Income | 116 | 240 | 185 | 107 | 150 | 333 | 484 | 136 | 214 | 180 | |
Total Income | 11,403 | 13,010 | 14,324 | 17,601 | 15,955 | 17,084 | 17,320 | 15,299 | 16,619 | 16,113 | |
Total Expenditure | -8,284 | -9,150 | -10,454 | -13,001 | -12,657 | -14,082 | -14,362 | -12,596 | -16,190 | -14,720 | |
PBIDT | 3,119 | 3,859 | 3,871 | 4,600 | 3,298 | 3,002 | 2,958 | 2,703 | 429 | 1,393 | |
Interest | -27 | -10 | -59 | -153 | -204 | -302 | -363 | -141 | -143 | -173 | |
Depreciation | -261 | -435 | -487 | -912 | -1,086 | -846 | -970 | -887 | -1,659 | -927 | |
Taxation | -962 | -970 | -1,059 | -979 | -288 | -902 | -1,147 | -449 | -137 | -209 | |
Exceptional Items | -1,464 | -340 | -752 | ||||||||
PAT | 1,870 | 2,444 | 2,265 | 2,556 | 255 | 612 | -274 | 1,227 | -1,510 | 85 | |
Minority Interest | -33 | -41 | -9 | -7 | -7 | -11 | -19 | -17 | |||
Share Associate | 5 | 8 | 4 | -5 | 4 | 1 | 0 | 0 | |||
Other Related Items | |||||||||||
Consolidated Net Profit | 1,836 | 2,403 | 2,261 | 2,557 | 251 | 607 | -269 | 1,217 | -1,528 | 68 | |
Adjusted EPS | 41 | 53 | 50 | 57 | 6 | 13 | -6 | 27 | -34 | 2 |
Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
Cash Fr. Operatn. | 1,251 | 2,004 | 2,733 | -382 | 4,114 | 1,751 | 1,666 | 1,469 | 1,822 | 367 | |
Cash Fr. Inv. | -522 | -859 | -1,055 | -6,962 | -2,527 | 470 | -3,282 | 1,107 | -1,240 | 1,292 | |
Cash Fr. Finan. | -663 | -857 | -197 | 5,836 | 433 | -1,492 | 744 | -891 | -1,885 | -1,572 | |
Net Change | 66 | 288 | 1,482 | -1,508 | 2,019 | 729 | -872 | 1,685 | -1,303 | 87 | |
Cash & Cash Eqvt | 311 | 607 | 2,108 | 780 | 2,799 | 1,416 | 544 | 2,229 | 926 | 1,013 |
Wed, 25 Jan 2023
Board Meeting Intimation for Considering And Taking On Record Unaudited Financial Results Of The Company For The Quarter And Nine-Months Ended December 31 2022. LUPIN LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/02/2023 inter alia to consider and approve unaudited financial results of the Company for the quarter and nine-months ended December 31 2022. |
Tue, 24 Jan 2023
Announcement under Regulation 30 (LODR)-Press Release / Media Release Lupin Launches LYFE its Digital Therapeutic Solution for Holistic Heart Care. |
Fri, 20 Jan 2023
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS Disclosure pursuant to allotment of 114899 shares under ESOP. |
Fri, 27 Jan 2023 |
|
|
|
|
|